Medical isotopes Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines medical isotope supply, the production, purification, generators and logistics that deliver lutetium-177, actinium-225 and related radionuclides to radioligand therapy programmes. It tests how fast new reactor, accelerator and legacy material capacity relieves the supply limit on radiopharmaceutical growth, and which participants capture value among producers, drug developers, logistics suppliers and hospitals.

Demand is already large for lutetium-177. Novartis reported 2025 net sales of USD 1,994 million for Pluvicto, up 43%, and USD 816 million for Lutathera, and it targets at least 250,000 doses a year across its manufacturing network. The conclusion is that commercial radioligand therapy has reached a scale at which isotope supply and delivery are the operating constraint, which became visible when Pluvicto was listed in shortage by the FDA from March to October 2023.

Actinium-225 is far tighter. Legacy thorium-229 generators yield roughly 63 GBq a year across four sites, enough for an estimated 100 to 200 patients annually, and RayzeBio paused enrolment in a Phase 3 trial in 2024 because of an actinium-225 shortage. The conclusion is that alpha therapy programmes depend on new production capacity, and trial timelines can move with isotope availability.

Capacity is now being added. TerraPower Isotopes announced a USD 450 million facility in Philadelphia in March 2026 that, with its Washington expansion, should raise capacity twentyfold, with production in 2029, and Niowave is building a USD 75 million actinium-225 plant in Lansing with operations in 2028. Cardinal Health said in April 2026 that weekly actinium-225 output had quadrupled since routine production began. The conclusion is that supply is expected to grow sharply by 2029, which places the tightest period in the near term.

The brief treats medical isotope supply as a high-impact category with a ten year horizon to 2036. It identifies which isotopes, regions and operators scale first and what each means for producers, drug developers, logistics suppliers and hospitals.

It is a focused 110-page decision brief for radiopharmaceutical firms, hospitals and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which isotopes scale first and who captures value.

Lutetium-177 has a half-life of about 6.6 days and is produced in reactors. The no-carrier-added form is used in approved radioligand therapies for prostate cancer and neuroendocrine tumours.

Actinium-225 has a half-life of about 10 days and is an alpha emitter. It is produced from thorium-229 generators, accelerators and, in newer routes, from legacy nuclear material or radium-226.

Lead-212 has a short half-life and is supplied through generators placed near the treatment site, which shifts the supply model toward regional production.

Uses are radioligand therapy and diagnostic imaging in oncology, each under radiopharmaceutical and radioactive material regulation.

The limits are decay during transport, shipment denials, dependence on enriched feedstocks, and the time needed to build and license facilities. The decade turns on whether capacity under construction arrives on schedule.

The medical isotopes market, covering production and supply of therapeutic and diagnostic radioisotopes including lutetium-177 and actinium-225, generators, and related radiolabelling, delivery and logistics services, is valued at USD 4–6 billion in 2026 and is projected to reach USD 14.83–22.24 billion by 2036, at a CAGR of 14%.

The 2026 base rests on lutetium-177 and diagnostic isotope supply, early actinium-225 sales, generators and logistics services. Growth then follows new actinium-225 plants, approvals of alpha therapies and regional supply of lead-212 and lutetium-177.

The forecast is sensitive to facility start dates, clinical results for alpha therapies, shipment rules and feedstock security. Regionally, North America leads on production and therapy sales, Europe on reactors and generator supply, and Asia-Pacific on diagnostic use and emerging capacity.

The base case assumes the facilities announced for 2028 and 2029 start on schedule and alpha therapies reach approval in the early 2030s, giving the inflection in 2032. An accelerated case assumes earlier plant start dates and a first alpha approval before 2030, bringing the inflection to 2030 and lifting the 2036 value to the top of the range. A delayed case assumes plant delays, shipment restrictions or feedstock shortages, holding growth at the bottom of the range.

Growth drivers

• Approved radioligand therapies in prostate cancer and neuroendocrine tumours.
• Alpha therapy programmes needing actinium-225.
• Trial enrolment limited by isotope supply.
• Large pharmaceutical investment in radiopharma.

Enablers

• Government isotope programmes and loans.
• Supply agreements between producers and drug developers.
• Public research funding.
• Reactor and accelerator infrastructure.

Restraints and barriers

• Short half-lives and fixed delivery schedules.
• Dependence on enriched feedstocks and legacy material.
• Shipment denials and transport licensing.
• Facility build times and licensing.

The direction of medical isotope supply is set by demand from radioligand therapy programmes, regulation, new production routes and feedstocks, treatment centre adoption and licensing, and manufacturing cost.

The key participants in medical isotopes include Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Bayer AG, Lantheus Holdings, Inc., Curium, Cardinal Health, Inc., TerraPower, LLC, Niowave, Inc., SHINE Technologies, LLC, NorthStar Medical Radioisotopes, LLC, ITM Isotope Technologies Munich SE, Orano SA, Nuclear Research and consultancy Group, Canadian Nuclear Laboratories, Telix Pharmaceuticals Limited, ARTBIO, Inc., Eckert & Ziegler SE, Global Morpho Pharma, Jubilant Pharmova Limited, Ionetix Corporation, Siemens Healthineers AG, Sanofi, University of Missouri Research Reactor Center, U.S. Department of Energy, International Atomic Energy Agency, Society of Nuclear Medicine and Molecular Imaging, European Association of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, Mayo Clinic, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, U.S. Nuclear Regulatory Commission, International Organization for Standardization, International Council for Harmonisation and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as medical isotope supply matures.

Cardinal Health, TerraPower, Niowave, SHINE Technologies, NorthStar Medical Radioisotopes and ITM lead the new production capacity, Novartis, Eli Lilly, Bristol-Myers Squibb and AstraZeneca drive demand through radioligand programmes, and CDMOs, logistics suppliers, hospitals, regulators and standards bodies shape how fast supply reaches patients. Competitive intensity is moderate in 2026 because supply is scarce and contracted, and it rises as new actinium-225 plants start production.

Where value migrates.

In 2026 value sits with producers that hold qualified commercial supply of lutetium-177 and early actinium-225, and with drug developers that have secured it under contract. By 2032 it moves toward companies with scaled alpha emitter supply, because approved alpha therapies need reliable volumes and the plants announced for 2028 and 2029 begin to deliver. By 2036 it settles in integrated isotope, drug and delivery networks that place production near treatment sites. Margins hold for qualified producers and narrow for late entrants as capacity grows.

The signals converge on rising demand and a lag in supply. Radioligand therapy sales passed USD 2.8 billion in 2025 for two products, actinium-225 from legacy generators serves only hundreds of patients a year, and capacity announced in 2026 starts producing between 2028 and 2029. Each signal supports growth, and the near term remains constrained.

Structural limits show where progress could slow: short half-lives, shipment denials, reliance on enriched feedstocks and the time to license new plants. The brief therefore tracks four indicators: facility start dates, actinium-225 output, supply agreements and shipment disruptions.

Lutetium-177 diversification, then actinium-225 scale, then regional lead-212 generator supply are the expected order of development.